Real-world Overall Survival with Abiraterone Acetate Versus Enzalutamide in Chemotherapy-naïve Patients with Metastatic Castration-resistant Prostate Cancer
Overview
Authors
Affiliations
Background: There are no large head-to-head phase 3 clinical trials comparing overall survival (OS) for abiraterone and enzalutamide. This study used Medicare claims data to compare OS in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated abiraterone or enzalutamide.
Methods: This retrospective analysis of the Medicare database (2009-2020) included adult men with ≥1 claim for prostate cancer, metastatic diagnosis, and no prior chemotherapy or novel hormone therapy who initiated first-line (1L) abiraterone or enzalutamide in the index period (September 10, 2014 to May 31, 2017). Cox proportional-hazards models with inverse probability treatment-weighting (IPTW) were used to compare OS between abiraterone- and enzalutamide-treated patients, adjusting for baseline characteristics. Subgroup analyses by baseline characteristics were also conducted.
Results: Overall, 5506 patients who received 1L abiraterone (n = 2911) or enzalutamide (n = 2595) were included. Median follow-up was comparable in both cohorts (abiraterone, 19.1 months; enzalutamide, 20.3 months). IPTW-adjusted median OS (95% CI) was 20.6 months (19.7‒21.4) for abiraterone and 22.5 months (21.2‒23.8) for enzalutamide, with an IPTW-adjusted hazard ratio (95% CI) of 1.10 (1.04-1.16). Median OS was significantly shorter for abiraterone versus enzalutamide in patients ≥75 years old; White patients; patients with baseline diabetes, cardiovascular disease, both diabetes and cardiovascular disease, and renal disease; and across all socioeconomic strata.
Conclusions: In the Medicare chemotherapy-naïve mCRPC population, 1L abiraterone was associated with worse OS versus enzalutamide in the overall population and among subgroups with older age and comorbidities, supporting findings from previous real-world studies and demonstrating a disparity in outcomes.
Aprikian A, Bahl A, Omlin A, Baciarello G, Chakravarty A, Kondaparthi P Front Oncol. 2025; 15:1491314.
PMID: 39995831 PMC: 11849621. DOI: 10.3389/fonc.2025.1491314.
Gopukumar D, Menon N, Schoen M JMIR Med Inform. 2024; 12:e59480.
PMID: 39561358 PMC: 11615563. DOI: 10.2196/59480.
Clinical outcomes in metastatic prostate adenocarcinoma treated with abiraterone and enzalutamide.
Soomro M, Khan S, Ishfaq H, Ali I, Samar M, Hameed A Ecancermedicalscience. 2024; 18:1763.
PMID: 39430091 PMC: 11489086. DOI: 10.3332/ecancer.2024.1763.
Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer.
La J, Wang L, Corrigan J, Lang D, Lee M, Do N JAMA Netw Open. 2024; 7(8):e2428444.
PMID: 39150709 PMC: 11329885. DOI: 10.1001/jamanetworkopen.2024.28444.